Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05143905
Other study ID # D9230C00001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 6, 2021
Est. completion date November 9, 2022

Study information

Verified date November 2022
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.


Description:

This is a Phase I, First-in-Human, study in healthy males and females (non-childbearing potential) participants. In this study up to four dose levels of AZD7503 are planned to be evaluated. The planned doses of AZD7503 are dose 1, dose 2, dose 3, and dose 4. Eligible participants will be randomised to receive either AZD7503 or placebo. The study will include four single dose cohorts with an option to include two cohorts based on emerging data from planned cohorts in the study and two additional cohorts of Japanese participants and one cohort of Chinese participants will also be included. Dosing for each ascending dose cohort will be proceeded with sentinel dosing strategy. Here, sentinel sub-cohort will be included, such that 1 participant will be randomised to receive placebo and 1 participant will be randomised to receive AZD7503. The safety data from the sentinel participants up to 24 hours post-dose will be reviewed by the Principal Investigator (PI) before the remaining participants in the cohort are dosed The study will comprise: - A Screening Period of maximum 28 days; - A Treatment Period during which participants will be resident at the Study Centre from the day before study medication administration (Day -1) until at least 72 hours after study medication administration; discharged from the Study Centre on Day 4; - Follow-up Visits on 1,2,4,6 and 8 weeks; and - A Final Follow-up Visit 10 weeks after the last study medication dose. Each participant will be involved in the study for approximately 14 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date November 9, 2022
Est. primary completion date November 9, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy non smoking male and/or female (of non childbearing potential) participants with suitable veins for cannulation or repeated venipuncture. - Females must have a negative pregnancy test at screening and on admission to the study centre, must not be lactating and must be of non childbearing potential. - Body mass index (BMI) between 18 and 30 kg/m^2, inclusive, and weigh at least 60 kg for healthy participants or between 18 and 32 kg/m^2, inclusive, and weigh at least 50 kg for Japanese and Chinese participants. - For Japanese and Chinese participants: 1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes first-, second-and third-generation Japanese whose parents or grandparents are living in a country other than Japan. 2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes first-, second-and third-generation Chinese whose parents or grandparents are living in a country other than China. - Willing to participate in retrospective genotyping analysis for HSD17B13. Exclusion Criteria: - History of any clinically important disease or disorder. - History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs. - Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of administration of study intervention. - Any laboratory values with the following deviations at screening and/or Day 1: - Alanine aminotransferase > Upper Limit of Normal (ULN) - Aspartate aminotransferase > ULN - Total bilirubin > ULN - Creatinine > ULN - White blood cell count < Lower Limit of Normal (LLN) - Hemoglobin < LLN - Estimated glomerular filtration rate < 60 mL/min/1.73 m^2 - Platelets >ULN and/or <LLN. - Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results other than those described above, including participants with platelet or bleeding disorders, known platelet dysfunction disorders. - Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or Human Immunodeficiency Virus. - Confirmed coronavirus disease 2019 (COVID-19) infection during screening and/or admission by polymerase chain reaction (PCR) test. - Abnormal vital signs, after 5 minutes supine rest - Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG. - Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months. - History of alcohol abuse or excessive intake of alcohol - History of Drug abuse or positive screen for drug of abuse or cotinine (nicotine) or alcohol. - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7503. - Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate) - Use of any prescribed or non prescribed medication during the 2 weeks prior to the administration of study intervention or longer if the medication has a long half-life. - Plasma donation within one month of screening or any blood donation/blood loss more than 500 mL during the 3 months prior to screening. - Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half lives, whichever is longer) of the administration of study intervention in this study. - Any ongoing or recent (ie, during the screening period) minor medical complaints. - Previous bone marrow transplant. - Non leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AZD7503
Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
Placebo
Randomised participants will receive placebo by SC injection

Locations

Country Name City State
United States Research Site Glendale California

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse Events (AEs) To assess adverse events as a variable of safety and tolerability of AZD7503 following SC single dose administration. Up to Final Follow-up (FU) Visit (Week 10) or Early Termination (ET) (assessed up to 14 Weeks)
Secondary Area under plasma concentration time-curve from zero to infinity (AUCinf) of AZD7503 To characterise the PK (AUCinf) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast) of AZD7503 To characterise the PK (AUClast) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Maximum observed plasma (peak) drug concentration (Cmax) of AZD7503 To characterise the PK (Cmax) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Time to reach peak or maximum observed concentration or response following drug administration (tmax) of AZD7503 To characterise the PK (tmax) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Time of last observed (quantifiable) concentration (tlast) of AZD7503 To characterise the PK (tlast) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Partial area under the plasma concentration-time curve from time 0 to time 48 hours post dose [AUC(0-48)] of AZD7503 To characterise the PK [AUC(0-48)] of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Half-life associated with terminal slope (?z) of a semi logarithmic concentration time curve (t½?z) of AZD7503 To characterise the PK (t½?z) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD7503 To characterise the PK (MRTinf) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD7503 To characterise the PK (CL/F) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Apparent volume of distribution at steady state following extravascular administration (Vz/F) of AZD7503 To characterise the PK (Vz/F) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
Secondary Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)] of AZD7503 To characterise the PK [Ae(t1-t2)] of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4
Secondary Percentage of dose excreted unchanged in urine from time t1 to t2 [Fe(t1-t2)] of AZD7503 To characterise the PK [Fe(t1-t2)] of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4
Secondary Renal clearance of drug from plasma (CLR) of AZD7503 To characterise the PK (CLR) of AZD7503 following SC administration of single ascending doses of AZD7503. (Pre-dose and Post-dose) Days 1 to 4
Secondary Number of participants with positive anti-drug antibodies (ADA) of AZD7503 To explore the formation of ADAs. Day -1 to final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks)
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1